You just read:

Prolong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE® in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory Setting

News provided by

Prolong Pharmaceuticals

Dec 13, 2017, 14:36 ET